SCHEMBL14907178

SCHEMBL14907178

Cc1ccncc1C(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT3 Q9NTG7 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GAA P10253 1/20 0.38
CYP2A6 P11509 4/20 0.35
CYP1A2 P05177 3/20 0.35
CYP2E1 P05181 3/20 0.35
CYP3A4 P08684 3/20 0.35
CYP2C8 P10632 3/20 0.35
CYP2D6 P10635 3/20 0.35
CYP2C9 P11712 3/20 0.35
CYP2B6 P20813 3/20 0.35
CYP2C19 P33261 3/20 0.35
CYP11B1 P15538 4/20 0.33
CYP11B2 P19099 4/20 0.33
TDO2 P48775 1/20 0.33
TRPA1 O75762 1/20 0.32
RPS6KA3 P51812 1/20 0.32
PTGS2 P35354 1/20 0.31
MPI P34949 1/20 0.31
CYP17A1 P05093 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25164691 0.84 SIRT3 (0.38) SIRT3TDP1GAACYP2A6CYP1A2
SCHEMBL20693003 0.82 TRPA1 (0.36) SIRT3TDP1GAACYP2A6CYP1A2
SCHEMBL179390 0.79 SIRT3 (0.41) SIRT3TDP1GAACYP2A6CYP1A2
SCHEMBL31188403 0.79 SIRT3 (0.41) SIRT3TDP1GAACYP2A6CYP1A2
SCHEMBL13838558 0.77 GAA (0.46) SIRT3TDP1GAACYP2A6CYP1A2
SCHEMBL28004351 0.77 SIRT3 (0.39) SIRT3TDP1GAACYP2A6CYP1A2
SCHEMBL26030475 0.76 RPS6KA3 (0.45) RPS6KA3
SCHEMBL25996380 0.76 RPS6KA3 (0.45) RPS6KA3
SCHEMBL22570349 0.76 SIRT3 (0.38) SIRT3TDP1GAACYP2A6CYP1A2
SCHEMBL21659210 0.76 SIRT3 (0.38) SIRT3TDP1GAACYP2A6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9221841-B2 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2015-12-29 US disclosed
US-20150191490-A1 MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2015-07-09 US disclosed
US-20140018399-A1 MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2014-01-16 US disclosed
US-8580828-B2 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2013-11-12 US disclosed
US-20130109656-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA, INC. 2013-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109656-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF KIF5B, KIF2C, KIFC1 SIRT3 1066/4885TDP1 179/4885GAA 426/4885
US-20150191490-A1 MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF KIF5B, KIF2C, KIFC1 SIRT3 1094/4885TDP1 239/4885GAA 405/4885
US-20140018399-A1 MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF KIF5B, KIF2C, KIFC1 SIRT3 1094/4885TDP1 239/4885GAA 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.